Press release
United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment Market to Reach USD 1.45 Billion by 2034
United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/48143
Key Takeaways
• Market Size (2024): USD 830 Million
• Forecast (2034): USD 1.45 Billion
• CAGR (2025-2034): 5.7 %
• Key Segments: Drug Class, Therapy Type, Distribution Channel, and End User
• Leading Companies: Eli Lilly and Company, Pfizer Inc., Novartis AG, Amgen Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., and Nevro Corp.
Market Story
Chemotherapy-Induced Peripheral Neuropathy (CIPN) affects nearly 40-60 % of cancer patients, causing chronic pain, tingling, and sensory loss. As oncology survival rates improve, clinicians and researchers are prioritizing neuroprotective and symptomatic-relief therapies to preserve long-term function.
Pharmaceutical pipelines are advancing serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and novel calcium-channel blockers, while medical-device innovators focus on neurostimulation, cryotherapy, and wearable pain-relief systems. AI-enabled symptom-tracking platforms integrated with electronic health records are emerging as critical tools for personalized neuropathy management in oncology centers across the U.S.
Market Segmentation
By Drug Class: Antidepressants (SNRIs, TCAs), Anticonvulsants, Opioids, Topical Analgesics, Others
By Therapy Type: Pharmacological, Physical Therapy, Neuromodulation, Cryotherapy, Acupuncture, Integrative Medicine
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By End User: Hospitals & Cancer Institutes, Specialty Pain Clinics, Home-Care Settings
Explore Full Report here: https://exactitudeconsultancy.com/reports/48143/united-states-chemotherapy-induced-peripheral-neuropathy-treatment-market
Recent Developments
• Pfizer Inc. initiated trials evaluating Duloxetine in combination with neuroprotective adjuvants for enhanced CIPN pain control.
• Nevro Corp. expanded its FDA-approved HFXTM spinal-cord-stimulation system to include oncology-related neuropathic pain indications.
• Amgen Inc. invested in pre-clinical studies of small-molecule neuro-regeneration agents targeting axonal repair.
• Astellas Pharma partnered with U.S. research institutes for Phase II evaluation of novel sodium-channel inhibitors for CIPN.
• Teva Pharmaceuticals introduced affordable generic formulations of gabapentinoids to expand patient access.
Expert Insight
"CIPN management is moving from reactive pain control to proactive nerve-protection strategies. Combination therapies and digital symptom monitoring are becoming the new standards in personalized oncology support,"
- Lead Analyst, Exactitude Consultancy
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=48143
Market Drivers
• Rising Cancer Prevalence: Over 1.9 million new cancer cases expected annually in the U.S.
• Innovation in Neuromodulation: Growing use of spinal-cord stimulators and non-invasive nerve-stimulation wearables.
• Patient-Centric Oncology: Emphasis on quality-of-life metrics within value-based care frameworks.
• Clinical-Trial Pipeline Growth: Increased R&D into neuroprotective drugs and regenerative compounds.
Forecast & Regional Insights
The United States leads global CIPN research and commercialization, accounting for nearly 45 % of worldwide market revenue (2024). High clinical-trial density, strong reimbursement infrastructure, and collaboration among academic hospitals, biotech firms, and pain-management centers sustain market momentum. Urban oncology hubs-particularly in California, Massachusetts, and Texas-are driving adoption of advanced digital-therapeutic and neuromodulation solutions.
Conclusion
The U.S. CIPN Treatment Market underscores the evolving landscape of supportive oncology care, where technology, pharmacology, and patient-centric approaches converge. As innovation accelerates in neuroprotection and rehabilitation, CIPN management is poised to become a defining pillar of comprehensive cancer recovery.
This report is also available in the following languages : Japanese (米国における化学療法誘発性末梢神経障害の治療), Korean (미국 화학요법 유발 말초신경병증 치료), Chinese (美国化疗诱发周围神经病变治疗), French (Traitement de la neuropathie périphérique induite par la chimiothérapie aux États-Unis), German (Behandlung der durch Chemotherapie verursachten peripheren Neuropathie in den Vereinigten Staaten), and Italian (Trattamento della neuropatia periferica indotta dalla chemioterapia negli Stati Uniti), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/48143/united-states-chemotherapy-induced-peripheral-neuropathy-treatment-market#request-a-sample
Related Reports
Chronic Pain associated with Painful Diabetic Neuropathy Market
https://exactitudeconsultancy.com/reports/70787/chronic-pain-associated-with-painful-diabetic-neuropathy-market
Chronic Neuropathic Pain Market
https://exactitudeconsultancy.com/reports/70792/chronic-neuropathic-pain-market
Chronic Pain associated with Painful Diabetic Neuropathy Market
https://exactitudeconsultancy.com/reports/70846/chronic-pain-associated-with-painful-diabetic-neuropathy-market
Sensory Neuropathy Market
https://exactitudeconsultancy.com/reports/71050/sensory-neuropathy-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment Market to Reach USD 1.45 Billion by 2034 here
News-ID: 4259299 • Views: …
More Releases from Exactitude Consultancy
Diaminodiphenylmethane (MDA & HDI) Monomer Market to Reach USD 4.8 Billion by 20 …
Pune, India - Exactitude Consultancy
The global Diaminodiphenylmethane (MDA & HDI) Monomer Market is expected to witness steady growth over the forecast period, driven by rising demand from polyurethane, adhesives, coatings, and chemical intermediate industries. The market was valued at approximately USD 2.3 billion in 2024 and is projected to reach around USD 4.8 billion by 2034, expanding at a compound annual growth rate (CAGR) of ~7.5% from 2025 to 2034.
Diaminodiphenylmethane…
Automotive ADAS Chip Market Accelerates as Demand for Advanced Vehicle Safety an …
Pune, India - Exactitude Consultancy - The global Automotive ADAS Chip Market is witnessing robust growth fueled by increasing deployment of advanced driver-assistance systems (ADAS) in passenger and commercial vehicles. Automotive ADAS chips, essential for sensor processing, decision-making, and vehicle safety features, are critical for applications such as lane departure warning, adaptive cruise control, collision avoidance, and autonomous driving.
Technological advancements in AI, sensor fusion, and semiconductor manufacturing are accelerating adoption,…
Home Audio Market Amplifies Growth as Smart and Connected Sound Systems Gain Pop …
Pune, India - Exactitude Consultancy - The global Home Audio Market is experiencing robust growth driven by increasing consumer preference for high-quality, immersive sound systems, smart home integration, and wireless connectivity. Home audio products, including soundbars, smart speakers, home theater systems, and multi-room audio solutions, are becoming integral to modern living spaces.
Technological innovations such as AI-driven audio optimization, voice assistants, and wireless connectivity are accelerating adoption across residential and commercial…
Nail Gel Market to Reach USD 5.1 Billion by 2034, Growing at 7.2% CAGR
Pune, India - Exactitude Consultancy
The global Nail Gel Market is witnessing significant growth, driven by increasing consumer preference for long-lasting, high-quality nail finishes, professional salon services, and at-home nail care kits. The market was valued at approximately USD 2.5 billion in 2024 and is projected to reach around USD 5.1 billion by 2034, expanding at a compound annual growth rate (CAGR) of ~7.2% during the forecast period.
Nail gels offer durability,…
More Releases for CIPN
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market to Surpass USD 2.6 Bill …
Pune, India, November 7, 2025 - The Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market is expected to expand from USD 1.2 billion in 2024 to nearly USD 2.6 billion by 2034, registering a CAGR of 8.0% during 2025-2034, according to Exactitude Consultancy. Rising use of neurotoxic chemotherapeutic agents such as platinum compounds, taxanes, and vinca alkaloids, coupled with advancing pain-management innovations, is driving sustained market growth.
Download Full PDF Sample Copy of…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Growing Focus and Marke …
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment, caused by damage to peripheral nerves from drugs such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. CIPN manifests as pain, numbness, tingling, and motor dysfunction, often leading to dose reduction or discontinuation of chemotherapy, which can compromise cancer outcomes.
With up to 68% of patients developing CIPN during chemotherapy, this condition represents a significant unmet…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline 2025: Groundbreaking …
With Chemotherapy Induced Peripheral Neuropathy (CIPN) reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Chemotherapy Induced Peripheral Neuropathy (CIPN). These therapies span various stages of clinical and…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market 2034: Clinica …
Chemotherapy Induced Peripheral Neuropathy companies working in the market are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Set to Experience Unpre …
DelveInsight's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Chemotherapy-Induced Peripheral Neuropathy (CIPN), historical and forecasted epidemiology as well as the Chemotherapy-Induced Peripheral Neuropathy (CIPN) market trends in the India, China, South Korea, Taiwan, and Australia.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis (2023) Cover …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy-Induced Peripheral Neuropathy (CIPN)…
